Show results for
Refine by
Therapeutic Antibody Suppliers Serving Cameroon
40 companies found
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
These drugs utilize the composition of various organisms and biological tissues, as well as organs. Biological drugs usually include genetic engineering drugs, antibody engineering drugs, blood products drugs, and vaccines etc. ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for PAD4 inhibitors in autoimmune ...
based inPaoli, NEW JERSEY (USA)
Beta Lifescience is a professional biotech company committed to providing premium quality life science research reagents worldwide across research and diagnostic markets. Our strong portfolio of recombinant proteins, viral antigens, antibodies, ...
Beta Lifesciences has accumulated an extensive experience in the development of recombinant proteins. We have rich experience in the expression of recombinant proteins (antibodies, enzymes, membrane proteins, cytokines, etc.) in any species. We ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Anti-Idiotype Ankyrons a game-changer for developing assays to track target-specific antibodies. Take the pain out of targeting the idiotype of your antibodies. Detecting and targeting specific antibody idiotypes is key for developing effective ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic ...
based inHertfordshire, UNITED KINGDOM
Fluidic Sciences Ltd specializes in microfluidic technologies for accelerating protein interaction analysis and single-cell screening. Their flagship product, Fluidity One-M, enables rapid measurements of binding affinity, concentration, ...
Fluidic Sciences Ltd. offers the Fluidity One-M instrument, integrated with Microfluidic Diffusional Sizing (MDS) technology, specifically engineered for in-solution analysis of antibodies and their targets throughout various stages ...
based inBaltimore, MARYLAND (USA)
SilcsBio provides software and services for unlocking the full potential of computer driven drug design. Our algorithms for mapping proteins will provide you with a level of detail you have never before experienced. From our highly accurate free ...
Leading-edge software builds on the patented SILCS technology, using protein-protein interaction and excipient binding predictions to give insights on excipient formulation for biological ...
based inMumbai, INDIA
Krishgen BioSystems (Krishgen) is privately-owned biotech firm with academic linkages to provide tools to scientists. With the strong background in immunology, we believe in the delivering quality kits, reagents and consumables. Certified and ...
Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF), was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
Creative Biolabs has extensive experience to offer the novel human or humanized antibody services for either therapeutic or laboratory applications. We have three routes in developing human ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inRochester Hills, MICHIGAN (USA)
Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company’s primary focus is on the identification and assay of biomarkers for ...